Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Apr 13

PMID 37046623

Authors

Antoine Gilbert

Mihaela Tudor

Juliette Montanari

Kevin Commenchail

Diana Iulia Savu

Paul Lesueur

Francois Chevalier

Affiliations

Soon will be listed here.

Abstract

Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma.

Citing Articles

Costal chondrosarcoma in a woman with hereditary multiple exostoses - a case report.

Yang Z, Wang K, Pu J Front Oncol. 2025; 15:1469072.

PMID: 40034594 PMC: 11873063. DOI: 10.3389/fonc.2025.1469072.

adioresistant, are, ecurrent, and adioinduced: 4s of Hadrontherapy for Patients Selections.

Vischioni B, Barcellini A, Magro G, Rotondi M, Durante M, Facoetti A Int J Part Ther. 2025; 15:100737.

PMID: 39927286 PMC: 11804719. DOI: 10.1016/j.ijpt.2024.100737.

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.

Li L, Hashemi L, Eid J, Tao W, Campoverde L, Yu A Int J Mol Sci. 2024; 25(23).

PMID: 39684713 PMC: 11641203. DOI: 10.3390/ijms252313003.

Enhancing Proton Radiosensitivity of Chondrosarcoma Using Nanoparticle-Based Drug Delivery Approaches: A Comparative Study of High- and Low-Energy Protons.

Tudor M, Popescu R, Irimescu I, Rzyanina A, Tarba N, Dinischiotu A Int J Mol Sci. 2024; 25(21).

PMID: 39519034 PMC: 11546389. DOI: 10.3390/ijms252111481.

Radiosensitizing Effect of PARP Inhibition on Chondrosarcoma and Chondrocyte Cells Is Dependent on Radiation LET.

Gilbert A, Tudor M, Delaunay A, Leman R, Levilly J, Atkinson A Biomolecules. 2024; 14(9).

PMID: 39334838 PMC: 11429578. DOI: 10.3390/biom14091071.

References

Cesaire M, Ghosh U, Austry J, Muller E, Cammarata F, Guillamin M . Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation. J Bone Oncol. 2019; 17:100246. PMC: 6609837. DOI: 10.1016/j.jbo.2019.100246. View

Amary M, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F . IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011; 224(3):334-43. DOI: 10.1002/path.2913. View

Nikoghosyan A, Rauch G, Munter M, Jensen A, Combs S, Kieser M . Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study. BMC Cancer. 2010; 10:606. PMC: 2991309. DOI: 10.1186/1471-2407-10-606. View

Boeuf S, Bovee J, Lehner B, Hogendoorn P, Richter W . Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology. 2010; 56(5):641-51. DOI: 10.1111/j.1365-2559.2010.03528.x. View

Durante M . New challenges in high-energy particle radiobiology. Br J Radiol. 2013; 87(1035):20130626. PMC: 4064605. DOI: 10.1259/bjr.20130626. View

Balosso J, Febvey-Combes O, Iung A, Lozano H, Alloh A, Cornu C . A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial. BMC Cancer. 2022; 22(1):575. PMC: 9128242. DOI: 10.1186/s12885-022-09564-7. View

Gelderblom H, Hogendoorn P, Dijkstra S, van Rijswijk C, Krol A, Taminiau A . The clinical approach towards chondrosarcoma. Oncologist. 2008; 13(3):320-9. DOI: 10.1634/theoncologist.2007-0237. View

Jones R, Katz D, Loggers E, Davidson D, Rodler E, Pollack S . Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Med Oncol. 2017; 34(10):167. PMC: 5574947. DOI: 10.1007/s12032-017-1030-2. View

Puri A . Chondrosarcomas in children and adolescents. EFORT Open Rev. 2020; 5(2):90-95. PMC: 7047903. DOI: 10.1302/2058-5241.5.190052. View

10.

Cozma G, Sima L, Closca R, Baderca F, Horhat I, Balica N . Conventional grade 1 chondrosarcoma: a challenging diagnosis with important implications on therapy and prognosis. Rom J Morphol Embryol. 2022; 62(2):605-613. PMC: 8848212. DOI: 10.47162/RJME.62.2.30. View

11.

Wang H, Jiang H, Van de Gucht M, De Ridder M . Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?. Cancers (Basel). 2019; 11(1). PMC: 6357097. DOI: 10.3390/cancers11010112. View

12.

Chaabane S, Bouaziz M, Drissi C, Abid L, Ladeb M . Periosteal chondrosarcoma. AJR Am J Roentgenol. 2008; 192(1):W1-6. DOI: 10.2214/AJR.08.1159. View

13.

Lohberger B, Barna S, Glanzer D, Eck N, Kerschbaum-Gruber S, Stasny K . Cellular and Molecular Biological Alterations after Photon, Proton, and Carbon Ions Irradiation in Human Chondrosarcoma Cells Linked with High-Quality Physics Data. Int J Mol Sci. 2022; 23(19). PMC: 9569755. DOI: 10.3390/ijms231911464. View

14.

Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs S, Jakel O . Carbon ion radiotherapy of skull base chondrosarcomas. Int J Radiat Oncol Biol Phys. 2006; 67(1):171-7. DOI: 10.1016/j.ijrobp.2006.08.027. View

15.

Yan Y, Liu F, Han L, Zhao L, Chen J, Olopade O . HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 2018; 37(1):256. PMC: 6194720. DOI: 10.1186/s13046-018-0925-x. View

16.

Holtzman A, Rotondo R, Rutenberg M, Indelicato D, Mercado C, Rao D . Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. J Neurooncol. 2019; 142(3):557-563. DOI: 10.1007/s11060-019-03129-8. View

17.

Kanemoto A, Hirayama R, Moritake T, Furusawa Y, Sun L, Sakae T . RBE and OER within the spread-out Bragg peak for proton beam therapy: in vitro study at the Proton Medical Research Center at the University of Tsukuba. J Radiat Res. 2014; 55(5):1028-32. PMC: 4202301. DOI: 10.1093/jrr/rru043. View

18.

Tosun I, Naderi S . Approach to Primary Vertebral Tumors in the Light of the 2020 Updated World Health Organization Classification of Bone Tumors. Turk Neurosurg. 2022; 33(1):1-9. DOI: 10.5137/1019-5149.JTN.36208-21.2. View

19.

Dungey F, Loser D, Chalmers A . Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys. 2008; 72(4):1188-97. DOI: 10.1016/j.ijrobp.2008.07.031. View

20.

Hamm C, Xie H, Costa F, Vanin E, Seftor E, Sredni S . Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity. PLoS One. 2009; 4(12):e8340. PMC: 2790612. DOI: 10.1371/journal.pone.0008340. View